ICARE-TNBC : Immune checkpoint-associated cardiotoxicity risk evaluation in early-stage triple-negative breast cancer

Clicks: 4
ID: 323440
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #124 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Triple-negative breast cancer (TNBC) is a particularly aggressive subtype that predominantly affects younger women. Pembrolizumab combined with chemotherapy improves outcomes in TNBC. However, anthracyclines, pembrolizumab and radiotherapy are potentially cardiotoxic but cardiovascular safety data in routine practice are limited. Purpose To describe cardiotoxicity and investigate predictive factors in patients treated with pembrolizumab, with or without anthracyclines, for early-stage TNBC. We hypothesised that baseline cardiovascular risk factors would predict cardiotoxicity. Methods We conducted a single-centre, retrospective observational study including 61 patients with triple-negative breast cancer treated between January 2022 and November 2024. The primary endpoint was a composite cardiotoxicity outcome defined according to ESC guidelines as cardiovascular death, cardiac dysfunction, myocarditis, pericarditis, arrhythmia or conduction disorder, acute coronary syndrome (ACS), or ischaemic stroke. Predictors were assessed using univariable Cox models; overall survival by Kaplan–Meier and log-rank, and cardiotoxicity incidence by cumulative incidence with competing risk of non-cardiovascular death. Results Among the 61 patients (mean age 55 ± 13 years), 33% were obese, 23% had hypertension, and 23% had dyslipidaemia. After a median follow-up of 14 months (IQR 10–21), cardiotoxicity occurred in 13% of patients with a median onset time of 6 (IQR 3–8) months. No cases of cardiovascular death were observed. 7% of patients presented with cardiac dysfunction, 2% with myocarditis, 2% with atrial fibrillation, 2% with ACS, and 2% with ischaemic stroke. Patients with cardiotoxicity had a higher rate of all-cause death than patients without cardiotoxicity (29% vs 4%; p<0.001). In univariable analysis, predictors of cardiotoxicity were age (HR 1.07; 95% CI 1.00–1.13; p=0.036), family history of coronary artery disease (HR 9.17; 95% CI 1.10–76.2; p=0.040), hypertension (HR 6.01; 95% CI 1.43–25.4; p=0.015), and reduced estimated glomerular filtration rate (HR 1.5; 95% CI 1.11–2.07; p=0.008). Conclusion In patients with early-stage TNBC treated with pembrolizumab, cardiotoxicity was frequent and associated with a significant reduction in overall survival. Larger prospective studies are required to better characterise predictors of cardiotoxicity in this setting.Annualised all-cause death events Cardiotoxicity by hypertension
Reference Key
openalex_W7172349697 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors L Dib, B Sibila, C Regragui, T Pezel, S Toupin, D Cochereau, C Cuvier, L Teixeira, F Azibani, A Cohen-Solal, D Logeart, J G Dillinger, P Henry, S Giachetti, T Goncalves
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.037
URL
https://doi.org/10.1093/eurheartjsupp/suag097.037
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.